- Conditions
- Leukemia
- Interventions
- lintuzumab, cytarabine, idarubicin
- Biological · Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1994 – 2003
- U.S. locations
- 1
- States / cities
- New York, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1129–1152
of 13,292
matching trials from the live ClinicalTrials.gov search.
- Conditions
- COVID-19
- Interventions
- PF-07817883
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 3
- States / cities
- Miami, Florida • Tampa, Florida • Saint Paul, Minnesota
- Conditions
- Eosinophilic Esophagitis
- Interventions
- Cendakimab, CYP substrates
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 12
- States / cities
- Tucson, Arizona • Los Angeles, California • San Diego, California + 9 more
- Conditions
- Leukemia, Myelodysplastic Syndromes
- Interventions
- Filgrastim, Cyclosporine, Decitabine, Allogeneic Bone Marrow Transplantation, Peripheral Blood Stem Cell Transplantation
- Biological · Drug · Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Up to 60 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1995 – 2002
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Fibromyalgia
- Interventions
- Desvenlafaxine Sustained Release (DVS SR), Lyrica® (Pregabalin), Placebo
- Drug
- Lead sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 27
- States / cities
- Huntsville, Alabama • Roseville, California • San Diego, California + 22 more
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- temozolomide 60 mg x 21 days, temozolomide 75 mg x 21 days, ABT-888 20 mg x 21 days, ABT-888 40 mg x 21 days, Temozolomide 150 mg x 5 days, ABT-888 40 mg x 5 days
- Drug
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 257 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 17
- States / cities
- La Jolla, California • Los Angeles, California • Honolulu, Hawaii + 11 more
- Conditions
- Myotonic Dystrophy Type 1 (DM1)
- Interventions
- VX-670
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 3
- States / cities
- St Louis, Missouri • Winston-Salem, North Carolina • Richmond, Virginia
- Conditions
- Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix, Gastrointestinal Stromal Tumor, Metastatic Gastrointestinal Carcinoid Tumor, Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Adult Primary Liver Cancer, Recurrent Anal Cancer, Recurrent Basal Cell Carcinoma of the Lip, Recurrent Colon Cancer, Recurrent Esophageal Cancer, Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Recurrent Extrahepatic Bile Duct Cancer, Recurrent Gallbladder Cancer, Recurrent Gastric Cancer, Recurrent Gastrointestinal Carcinoid Tumor, Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Recurrent Lymphoepithelioma of the Nasopharynx, Recurrent Lymphoepithelioma of the Oropharynx, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Recurrent Mucoepidermoid Carcinoma of the Oral Cavity, Recurrent Non-small Cell Lung Cancer, Recurrent Pancreatic Cancer, Recurrent Rectal Cancer, Recurrent Salivary Gland Cancer, Recurrent Small Intestine Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Small Intestine Adenocarcinoma, Small Intestine Leiomyosarcoma, Small Intestine Lymphoma, Stage IV Adenoid Cystic Carcinoma of the Oral Cavity, Stage IV Anal Cancer, Stage IV Basal Cell Carcinoma of the Lip, Stage IV Colon Cancer, Stage IV Esophageal Cancer, Stage IV Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Stage IV Gastric Cancer, Stage IV Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Stage IV Lymphoepithelioma of the Nasopharynx, Stage IV Lymphoepithelioma of the Oropharynx, Stage IV Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Stage IV Mucoepidermoid Carcinoma of the Oral Cavity, Stage IV Non-small Cell Lung Cancer, Stage IV Pancreatic Cancer, Stage IV Rectal Cancer, Stage IV Salivary Gland Cancer, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Oropharynx, Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IV Verrucous Carcinoma of the Larynx, Stage IV Verrucous Carcinoma of the Oral Cavity, Tongue Cancer, Unresectable Extrahepatic Bile Duct Cancer, Unresectable Gallbladder Cancer
- Interventions
- cetuximab, erlotinib hydrochloride, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Diabetes Mellitus and Heart Failure
- Interventions
- LIK066, Placebo, Empagliflozin
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 21
- States / cities
- Huntsville, Alabama • Carmichael, California • Concord, California + 18 more
- Conditions
- Advanced Adult Hepatocellular Carcinoma, Child-Pugh Class A, Stage III Hepatocellular Carcinoma, Stage IIIA Hepatocellular Carcinoma, Stage IIIB Hepatocellular Carcinoma, Stage IIIC Hepatocellular Carcinoma, Stage IV Hepatocellular Carcinoma, Stage IVA Hepatocellular Carcinoma, Stage IVB Hepatocellular Carcinoma
- Interventions
- Laboratory Biomarker Analysis, Pembrolizumab, Sorafenib Tosylate
- Other · Biological · Drug
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • Buffalo, New York
- Conditions
- Breast Cancer, Ovarian Cancer
- Interventions
- aldesleukin, p53 peptide vaccine, in vitro-treated peripheral blood stem cell transplantation
- Biological · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2006
- U.S. locations
- 2
- States / cities
- Bethesda, Maryland
- Conditions
- Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia, Adult Acute Erythroid Leukemia (M6), Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monoblastic Leukemia and Acute Monocytic Leukemia (M5), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Childhood Acute Basophilic Leukemia, Childhood Acute Eosinophilic Leukemia, Childhood Acute Erythroleukemia (M6), Childhood Acute Megakaryocytic Leukemia (M7), Childhood Acute Minimally Differentiated Myeloid Leukemia (M0), Childhood Acute Monoblastic Leukemia (M5a), Childhood Acute Monoblastic Leukemia and Acute Monocytic Leukemia (M5), Childhood Acute Monocytic Leukemia (M5b), Childhood Acute Myeloblastic Leukemia With Maturation (M2), Childhood Acute Myeloblastic Leukemia Without Maturation (M1), Childhood Acute Myelomonocytic Leukemia (M4), Childhood Myelodysplastic Syndromes, de Novo Myelodysplastic Syndromes, Untreated Adult Acute Myeloid Leukemia, Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies
- Interventions
- cytarabine, daunorubicin hydrochloride, etoposide, valspodar, filgrastim, busulfan, autologous hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, aldesleukin, clinical observation, pharmacological study
- Drug · Biological · Procedure + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 15 Years to 59 Years
- Enrollment
- 720 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Ocular Myasthenia Gravis
- Interventions
- Rozanolixizumab, Placebo
- Drug
- Lead sponsor
- UCB Biopharma SRL
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 6
- States / cities
- Scottsdale, Arizona • O'Fallon, Illinois • Amherst, New York + 3 more
- Conditions
- Polymyalgia Rheumatica
- Interventions
- Sarilumab, Placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 47
- States / cities
- Avondale, Arizona • Phoenix, Arizona • Tucson, Arizona + 42 more
- Conditions
- Melanoma
- Interventions
- fianlimab, cemiplimab, relatlimab+nivolumab
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 560 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2033
- U.S. locations
- 106
- States / cities
- Chandler, Arizona • Gilbert, Arizona • Tucson, Arizona + 87 more
- Conditions
- Myotonic Dystrophy Type 1 (DM1)
- Interventions
- VX-670, Placebo
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 8
- States / cities
- San Carlos, California • Gainesville, Florida • Fairway, Kansas + 5 more
- Conditions
- Cognitive Decline, Cognitive Impairment
- Interventions
- Vitamin D
- Other
- Lead sponsor
- National Institute on Aging (NIA)
- NIH
- Eligibility
- 30 Years to 64 Years
- Enrollment
- 3,720 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2004 – 2013
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Treatment Resistant Depression, Major Depressive Disorder, Treatment-Refractory Depression, Late Life Depression, Geriatric Depression
- Interventions
- Aripiprazole Augmentation, Bupropion Augmentation, Switch to bupropion, Lithium Augmentation, Switch to nortriptyline
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 742 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 4
- States / cities
- Los Angeles, California • St Louis, Missouri • New York, New York + 1 more
- Conditions
- Depressive Disorder, Major
- Interventions
- Vortioxetine, Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 469 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 61
- States / cities
- Little Rock, Arkansas • Carson, California • Cerritos, California + 58 more
- Conditions
- Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention
- Interventions
- ExPEC9V, Placebo, HD quadrivalent influenza vaccine
- Biological
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 65 Years and older
- Enrollment
- 959 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 24
- States / cities
- Huntsville, Alabama • Mobile, Alabama • San Diego, California + 19 more
- Conditions
- Major Depressive Disorder
- Interventions
- ALKS 5461
- Drug
- Lead sponsor
- Alkermes, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 1,485 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 123
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 105 more
- Conditions
- Obesity, Overweight, Chronic Weight Management
- Interventions
- ASC30 tablets A1, Placebo
- Drug
- Lead sponsor
- Ascletis Pharma (China) Co., Limited
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3,003 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 69
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 65 more
- Conditions
- Bacterial Pneumonia
- Interventions
- Ceftaroline fosamil for Injection, Ceftriaxone, Placebo
- Drug
- Lead sponsor
- Forest Laboratories
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 622 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Functional Disability, Obesity, Physical Inactivity
- Interventions
- Diet and physical activity, Physical activity control
- Behavioral · Other
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 65 Years to 100 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2008
- U.S. locations
- 1
- States / cities
- McKeesport, Pennsylvania